Congrats, you’re almost there! 

Now that you’ve finished your mobile view, tidy up your landing page by deleting template instructions or unneeded page sections.

Let’s publish (don’t worry it will only be visible to you). 

A. Click ‘Save’, 

B. Navigate back to the Page Overview screen 

C. Click Publish

While the ASX is known for its banks and its miners, it has its fair share of healthcare and biotech companies with compelling value propositions for investors.

There’s no shortage of healthcare companies on the ASX, providing investors with exposure to over 200 companies within the sector. But, to deliver results and value to investors, several steps must be followed when considering the development of treatments and medications that these companies aim to offer.

The question is then; What does it take to get one of these developments to market in Australia?
 
In this special event, learn of the processes that healthcare companies need to follow to attain approvals and how the trial phases work. In addition, gain valuable insights on whats moving the sector, as well as some of the most notable entities within the space.
 
Join guest speakers from ASX healthcare companies, including:
  • Recce Pharmaceuticals Ltd (ASX:RCE): Chief Scientific Officer, Michele Dilizia
  • BlinkLab Ltd (ASX:BB1): Chairman, Brian Leedman
  • Race Oncology Ltd (ASX:RAC): CEO, Daniel Tillett
  • Bioshares: Editor, Mark Pachacz


Attendees will also have the opportunity to take part in a live Q+A with panel participants.

© 2024 HotCopper. All Rights Reserved.

Register for FREE today

TIME

10am AWST / 
12pm AEST 

DATE

Thursday, May 23rd 2024

Don't miss this unique opportunity!

Register for FREE today
About HotCopper
Australia's top stock market forum, uniting the largest community of active ASX investors. Partnering with The Market Online, we're extending our reach to deliver a wealth of investment knowledge, insights and trends on the ASX and NZX to a diverse and affluent audience.
About The Market Online
A comprehensive and timely financial news platform, providing the latest on capital markets in Australia and Canada. Committed to delivering insightful analyses, actionable news, and breaking stories, The Market Online empowers investors with what’s needed for informed investment decisions.
About The Market Link
The only connection to Australia’s largest online community of investors. Using our ecosystem of proprietary platforms, we help listed companies and wealth brands refine, grow, and measure their digital presence through diverse advertising and communication solutions.

Participating Companies

Register for FREE today
Race Oncology Ltd (ASX:RAC)

Race Oncology aims to develop new drugs to better treat cancer patient that avoid the serious side effects of cancer therapies. Race’s lead drug bisantrene is a broad-acting, small molecule chemotherapeutic with an extensive clinical history and therapeutic benefits in both adult and paediatric patients. Race is advancing a reformulated version of bisantrene (RC220) to address the high unmet needs of cancer patients for improved anticancer treatments while avoiding the heart damage caused by other chemotherapies. Race is also exploring RC220 as a low intensity treatment for Acute Myeloid Leukaemia. Race is supported by an experienced leadership team and expert advisors who are commitment to advancing novel cancer therapies.

Recce Pharmaceuticals Ltd (ASX:RCE; FSE:R9Q)

Recce Pharmaceuticals is developing a new class of synthetic anti-infectives to address the global health issues of antibiotic-resistant superbugs. Their pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327, RECCE® 435 and RECCE® 529. These anti-infectives, with multi-layered mechanisms of action, have the potential to overcome resistance processes in bacteria. Along with its Fast Track Designation by the FDA and inclusion in prestigious global antibiotic pipelines (WHO and PEW Charitable Trusts), underscores its potential to combat antibiotic resistance. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

BlinkLab Ltd (ASX:BB1)

BlinkLab is the world’s first AI-driven digital healthcare venture, pioneering autism and ADHD detection through smartphone facial recognition and computer vision. Spearheaded by Chairman Brian Leedman, co founder of ResApp Health, BlinkLab’s breakthrough technology, from Princeton University research, promises to replicate past successes while revolutionising diagnosis and patient care.